Biontech and regeneron expand strategic collaboration to advance clinical development of fixvac and libtayo® (cemiplimab) combination in nsclc

Mainz, germany , march 8, 202 2 (globe newswire) -- biontech se (nasdaq: bntx, “biontech” or “the company”) today announced the expansion of its strategic collaboration with regeneron to advance the company's fixvac candidate bnt116 in combination with libtayo® (cemiplimab), a pd-1 inhibitor, in advanced non-small cell lung cancer (nsclc). under the terms of the agreement the companies plan to jointly conduct clinical trials to evaluate their combination in different patient populations with advanced nsclc. lung cancer is worldwide one of the most common diagnosed malignant cancer types and the leading cause of cancer death. 1 nsclc is the most common type of lung cancer, making up about 85% of all lung cancers.
BNTX Ratings Summary
BNTX Quant Ranking